The analysis covers three biotech stocks: LLY, VKTX, and BIIB. LLY is presented as a conservative, bullish pick with significant growth potential in the obesity and diabetes markets, currently trading around $1047.47 and targeting $1132.94, with a fail bound at $1000. VKTX, a pre-revenue company with a strong year in 2025, shows promising clinical trial results for its obesity and NASH drug candidates. It is trading around $33.68 and analysts have a target of $46.34, with a failure point at $30. BIIB is discussed as a more speculative play due to its significant short interest and the potential for its Alzheimer's and other neurological drugs to drive growth. It's currently trading around $164.89, with a target of $225 and a fail bound at $143. Analysts are bullish on all three, expecting further upside driven by pipeline development and market demand for their respective therapies.